Apotex Ruxolitinib US Approval Date
Apotex's ruxolitinib topical foam (15% concentration, branded as Opzelura) gained FDA approval on September 21, 2021, for treating mild to moderate atopic dermatitis in non-immunocompromised patients aged 12 years and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.[1]
What Conditions Does It Treat?
The approval covers short-term (up to 8 weeks) and non-continuous chronic therapy for atopic dermatitis. In 2022, the FDA expanded the label to include nonsegmental vitiligo in patients aged 12 and older, making it the first pharmacologic treatment approved for repigmentation in this condition.[1][2]
How Does It Differ from Incyte's Jakafi?
Apotex's version is a topical foam formulation distinct from Incyte's oral ruxolitinib (Jakafi), approved in 2011 for myelofibrosis and later polycythemia vera. Opzelura targets skin conditions via JAK1/JAK2 inhibition applied directly, avoiding systemic exposure.[1][3]
Biosimilar or Generic Status?
Apotex's Opzelura is an FDA-approved branded product licensed from Incyte, not a generic or biosimilar. No generics for topical ruxolitinib exist yet; oral Jakafi generics face patent challenges, with some ANDAs approved but launches pending litigation.[4]
Patent Expiry and Competition
Incyte holds patents on ruxolitinib formulations through the mid-2030s; DrugPatentWatch lists key U.S. patents expiring no earlier than 2033, with Paragraph IV challenges from competitors like Celgene and others potentially delaying generics.[5] Apotex partnered with Incyte for development, not as a challenger.
[1] FDA approval announcement: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-topical-treatment-repigmentation-vitiligo-patients-aged-12-and-older
[2] FDA label expansion: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-ruxolitinib-opzelura-cream-repigmentation-due-nonsegmental-vitiligo
[3] Jakafi approval history: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202192lbl.pdf
[4] FDA Orange Book for ruxolitinib: https://www.accessdata.fda.gov/scripts/cder/ob/
[5] DrugPatentWatch ruxolitinib patents: https://www.drugpatentwatch.com/p/tradename/JAKAFI